In November 2024, a regulatory advisory board said the benefits of Zynquista does not outweigh the risks in adults with type ...

Take a look at this year’s top articles — one showcasing enhanced weight loss through Semaglutide use in post-menopausal ...

Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...

Kamilia Smith, MD, FACOG, NCMP, discusses how educating patients about the serious long-term health risks of untreated vasomotor symptoms (VMS) requires a comprehensive strategy that includes clear ...

This year’s top dermatology posts on Managed Healthcare Executive include stories about Gen Z sunscreen trends and increasing ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

Historically, healthcare organizations have considered the contact center to be a cost center, a communications platform for ...

The boxed warning follows a safety warning the FDA issued in September about the risk of liver injury from the use of Veozah ...

Take a look at the best performing print articles of 2024. This year's top article spotlights the surge of mRNA vaccines ...

Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain ...

One of this year's top articles on cost and coverage highlights that the average American can afford a maximum of $97 in ...

Take a look at the best performing print articles of 2024. This year's top article spotlights the surge of mRNA vaccines ...